Trial
NCT03817190
Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
DS Biopharma
Collaborators
—
Condition
Atopic Dermatitis
Intervention
DS107
Why stopped
Based on Interim Analysis results
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-28